Stockreport

Structure Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights [Yahoo! Finance]

Structure Therapeutics Inc.  (GPCR) 
PDF Plan to initiate dosing in first-in-human Phase 1 clinical trial of oral small molecule LPA1R Antagonist, LTSE-2578, for idiopathic pulmonary fibrosis in June 2024 SA [Read more]